CN1148372C - 具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物 - Google Patents

具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物 Download PDF

Info

Publication number
CN1148372C
CN1148372C CNB988028875A CN98802887A CN1148372C CN 1148372 C CN1148372 C CN 1148372C CN B988028875 A CNB988028875 A CN B988028875A CN 98802887 A CN98802887 A CN 98802887A CN 1148372 C CN1148372 C CN 1148372C
Authority
CN
China
Prior art keywords
group
following formula
compound
ring
represented
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CNB988028875A
Other languages
English (en)
Chinese (zh)
Other versions
CN1260798A (zh
Inventor
��Ұ���
水野章
柴田诚
����һ
龟位智惠
深见治一
猪俣则夫
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Asubio Pharma Co Ltd
Original Assignee
Suntory Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Suntory Ltd filed Critical Suntory Ltd
Publication of CN1260798A publication Critical patent/CN1260798A/zh
Application granted granted Critical
Publication of CN1148372C publication Critical patent/CN1148372C/zh
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/08—Vasodilators for multiple indications
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
CNB988028875A 1997-12-26 1998-12-25 具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物 Expired - Fee Related CN1148372C (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9366756A JPH11193289A (ja) 1997-12-26 1997-12-26 ピロールスルホンアミド誘導体
JP366756/1997 1997-12-26

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CNB2004100396861A Division CN1282643C (zh) 1997-12-26 1998-12-25 用于制备具有5－羟色胺－2受体拮抗作用和α1－阻断作用的化合物的中间体及其制法

Publications (2)

Publication Number Publication Date
CN1260798A CN1260798A (zh) 2000-07-19
CN1148372C true CN1148372C (zh) 2004-05-05

Family

ID=18487593

Family Applications (2)

Application Number Title Priority Date Filing Date
CNB988028875A Expired - Fee Related CN1148372C (zh) 1997-12-26 1998-12-25 具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物
CNB2004100396861A Expired - Fee Related CN1282643C (zh) 1997-12-26 1998-12-25 用于制备具有5－羟色胺－2受体拮抗作用和α1－阻断作用的化合物的中间体及其制法

Family Applications After (1)

Application Number Title Priority Date Filing Date
CNB2004100396861A Expired - Fee Related CN1282643C (zh) 1997-12-26 1998-12-25 用于制备具有5－羟色胺－2受体拮抗作用和α1－阻断作用的化合物的中间体及其制法

Country Status (9)

Country Link
US (3) US6271223B1 (enExample)
EP (1) EP0970088A2 (enExample)
JP (1) JPH11193289A (enExample)
KR (1) KR20000075641A (enExample)
CN (2) CN1148372C (enExample)
AU (1) AU752095B2 (enExample)
CA (1) CA2282458A1 (enExample)
HU (1) HUP0002291A3 (enExample)
WO (1) WO1999033840A2 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1997020845A1 (fr) 1995-12-01 1997-06-12 Suntory Limited Derives de pyrroloazepine
JPH11193290A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
US6960579B1 (en) 1998-05-19 2005-11-01 Alcon Manufacturing, Ltd. Serotonergic 5HT7 receptor compounds for treating ocular and CNS disorders
AU784462B2 (en) * 2000-03-31 2006-04-06 Purdue Research Foundation Phosphoramidate prodrugs
IL283725B2 (en) 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
WO2020081361A1 (en) 2018-10-17 2020-04-23 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds
US11780811B2 (en) 2020-06-30 2023-10-10 Imbria Pharmaceuticals, Inc. Methods of synthesizing 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11530184B2 (en) 2020-06-30 2022-12-20 Imbria Pharmaceuticals, Inc. Crystal forms of 2-[4-[(2,3,4-trimethoxyphenyl)methyl]piperazin-1-yl]ethyl pyridine-3-carboxylate
US11883396B2 (en) 2021-05-03 2024-01-30 Imbria Pharmaceuticals, Inc. Methods of treating kidney conditions using modified forms of trimetazidine

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US240178A (en) 1881-04-12 Feeding device for button-hole sewing-machines
US208631A (en) 1878-10-01 Improvement in trimmers for wax-thread sewing-machines
US236765A (en) 1881-01-18 Attoenet
JP3198117B2 (ja) 1990-02-07 2001-08-13 サントリー株式会社 ピロロアゼピン誘導体
US5075440A (en) 1990-05-03 1991-12-24 Ortho Pharmaceutical Corporation Novel pyrido[2,3-f](1,4)thiazepines and pyrido[3,2-b](1,5)benzothiazepines
FR2675802B1 (fr) * 1991-04-26 1993-12-24 Rhone Poulenc Rorer Sa Antiserotonines, leur preparation et les medicaments les contenant.
WO1993003032A1 (fr) 1991-08-07 1993-02-18 Suntory Limited Compose de pyrroloazepine
CA2093631C (en) 1991-08-07 2003-09-23 Akira Mizuno Pyrroloazepine derivative
IL108634A0 (en) * 1993-02-15 1994-05-30 Wellcome Found Hypolipidaemic heterocyclic compounds, their prepatation and pharmaceutical compositions containing them
AU690622B2 (en) * 1993-12-24 1998-04-30 Daiichi Suntory Pharma Co., Ltd Benzothiazine derivative
DE69630184T2 (de) 1995-11-02 2004-08-12 Daiichi Suntory Pharma Co., Ltd. Verfahren zur Herstellung von 1-substituierten Pyrrol-3-carbonsäure-Derivaten
WO1997020845A1 (fr) 1995-12-01 1997-06-12 Suntory Limited Derives de pyrroloazepine
JPH10251258A (ja) 1997-03-14 1998-09-22 Suntory Ltd ピロロアゼピン系化合物
JPH11193289A (ja) 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド誘導体
JPH11193290A (ja) * 1997-12-26 1999-07-21 Suntory Ltd ピロールスルホンアミド系化合物

Also Published As

Publication number Publication date
US7057036B2 (en) 2006-06-06
CN1282643C (zh) 2006-11-01
CA2282458A1 (en) 1999-07-08
KR20000075641A (ko) 2000-12-26
US20020040017A1 (en) 2002-04-04
CN1260798A (zh) 2000-07-19
HUP0002291A3 (en) 2002-12-28
WO1999033840B1 (en) 1999-10-14
US6271223B1 (en) 2001-08-07
AU1690699A (en) 1999-07-19
AU752095B2 (en) 2002-09-05
US6624314B2 (en) 2003-09-23
CN1528746A (zh) 2004-09-15
WO1999033840A3 (en) 1999-09-10
US20050038242A2 (en) 2005-02-17
EP0970088A2 (en) 2000-01-12
WO1999033840A2 (en) 1999-07-08
US20040127705A1 (en) 2004-07-01
JPH11193289A (ja) 1999-07-21
HUP0002291A2 (hu) 2001-04-28

Similar Documents

Publication Publication Date Title
CN1163484C (zh) 4-芳酰基-哌啶-ccr-3受体拮抗剂ⅲ
CN1118452C (zh) 1－[(1－取代－4－哌啶基)甲基]－4－哌啶衍生物、其生产方法、含有该化合物的药物组合物和这些化合物的中间体
CN100351236C (zh) 用作5－羟色胺－6配体的1－杂环基烷基－3－磺酰基－吲哚衍生物，其制备方法和用途
CN1150165C (zh) 用于治疗中枢神经系统紊乱的1-芳基磺酰基-2-芳基-吡咯烷衍生物
CN1468216A (zh) 含氮五员环化合物
CN1374953A (zh) 含氮的6－员芳香环化合物
CN1083062A (zh) 异羟肟酸衍生物
CN1018614B (zh) 制备含n-杂环基-4-哌啶胺类的抗组胺组合物的方法
CN1794987A (zh) 具有提高的抗炎、抗血栓形成和抗血小板活性的作为降胆固醇药的氟伐他汀、普伐他汀、西立伐他汀、阿托伐他汀和罗苏伐他汀的硝基氧基衍生物
CN1929737A (zh) Hiv整合酶抑制剂
CN1119856A (zh) Hiv逆转录酶抑制剂
CN1856477A (zh) 异喹啉钾通道抑制剂
CN1148372C (zh) 具有5－羟色胺－2受体拮抗作用和α1-阻断作用的吡咯噻嗪和吡咯硫杂吖庚因化合物
CN1503797A (zh) 吡啶并嘧啶或二氮杂萘衍生物
CN1780820A (zh) 作为阿立新受体拮抗剂的喹喔啉－3－酮衍生物
CN100338074C (zh) 杂环化合物和以其为有效成分的脑机能改善剂
CN1178923C (zh) 1,4-二氮杂环庚烷-2,5-二酮衍生物及其作为nk-1受体拮抗剂的应用
CN1993358A (zh) 作为趋化因子受体拮抗剂的噻唑衍生物
CN1210273C (zh) 取代的3－吡啶基－4－芳基吡咯及治疗和预防相关疾病的方法
CN1245400C (zh) N－取代苯并噻唑磺胺衍生物
CN1155570C (zh) 新的氰基-吲哚5-羟色胺再摄取抑制剂化合物、其制备方法和含有它们的药物组合物
CN1099752A (zh) 新型酰氨烷基-和亚氨烷基-哌嗪
CN1193014C (zh) 新的吡咯磺酰胺化合物
CN1665506A (zh) 作为ccr－3受体拮抗剂ⅸ的2,5－取代的嘧啶衍生物
CN1094126C (zh) 吡咯并吖庚因化合物

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
ASS Succession or assignment of patent right

Owner name: SUNTORY LTD

Free format text: FORMER OWNER: SUNTORY LTD.

Effective date: 20030418

C41 Transfer of patent application or patent right or utility model
TA01 Transfer of patent application right

Effective date of registration: 20030418

Address after: Tokyo, Japan

Applicant after: SUNTORY LTD.

Address before: Osaka

Applicant before: Suntory Ltd.

C14 Grant of patent or utility model
GR01 Patent grant
C56 Change in the name or address of the patentee

Owner name: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: SUNTORY LTD

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: DAIICHI ASUBIO PHARMA CO.,LTD.

Address before: Tokyo, Japan

Patentee before: SUNTORY LTD.

C56 Change in the name or address of the patentee

Owner name: ASTERIX PHARMACEUTICAL CO., LTD.

Free format text: FORMER NAME OR ADDRESS: THE FIRST ASHBIAO PHARMACEUTICAL CO., LTD.

CP01 Change in the name or title of a patent holder

Address after: Tokyo, Japan

Patentee after: ASUBIO PHARMA Co.,Ltd.

Address before: Tokyo, Japan

Patentee before: DAIICHI ASUBIO PHARMA CO.,LTD.

C19 Lapse of patent right due to non-payment of the annual fee
CF01 Termination of patent right due to non-payment of annual fee